Phase 3 Oesophageal Cancer Trial, Recruiting NCT04460352 Sponsor: Karolinska University Hospital Condition: Oesophageal Cancer
Back to Oesophageal Cancer

Phase 3 Oesophageal Cancer Trial, Recruiting

NCT04460352
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with squamous cell cancer of the esophagus (food pipe) that has been confirmed by a tissue sample, and the cancer is at a locally advanced stage but has not spread to distant parts of the body.
  • A specialist medical team has agreed that your cancer can be surgically removed.
  • You are generally active and able to carry out daily activities with little or no restriction (as measured by a standard health scale).
  • Your organs (such as kidneys, liver, and heart) are working well enough to participate.
  • If you are a woman who could become pregnant, you must have a negative pregnancy test before joining.
  • If you could become pregnant or father a child, you must use a highly effective form of contraception during the study and for at least five months after the last treatment.
  • If you are currently breastfeeding, you must stop before receiving the first treatment.
  • You are able to attend all required appointments and follow the study schedule without major barriers.
  • You are willing and able to give written consent to take part in the trial.

Who may not be able to join:

  • Your cancer has already spread to distant parts of the body.
  • Your tumor has grown into nearby structures in a way that makes it very difficult to remove (confirm with trial site).
  • Your tumor cannot be removed surgically without also removing your voice box (larynx).
  • You have serious problems with your kidneys, liver, heart, lungs, or hormonal system that would make combination treatment too risky.
  • Your doctors do not think you are likely to tolerate the combination of chemotherapy, radiotherapy, and surgery.
  • You have had a previous cancer in the last 5 years, unless it was completely treated or removed at least 5 years ago.
  • You have previously had radiotherapy or chemotherapy with radiotherapy in an area that would overlap with the treatment area for this trial.
  • You have a known serious allergic reaction to any of the chemotherapy drugs used in this trial.
  • You are unable to understand the study information or follow the study instructions due to language barriers, dementia, or a severe mental health condition.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Magnus Nilsson, MD, PhD, Karolinska University Hospital

Phone: +46-707-375186

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Karolinska University Hospital
Registry
ClinicalTrials.gov
Start date
27 November 2020
Est. completion
31 December 2026

Where this trial is recruiting

🇨🇦 Canada 🇮🇪 Ireland 🇳🇴 Norway 🇸🇪 Sweden 🇹🇼 Taiwan

Primary endpoints

Overall survival; Global Health-related quality of life (HRQOL); Eating restrictions

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov